Edition:
United States

WAVE Life Sciences Ltd (WVE.OQ)

WVE.OQ on NASDAQ Stock Exchange Global Market

39.10USD
12:28pm EDT
Change (% chg)

$-1.38 (-3.40%)
Prev Close
$40.47
Open
$41.30
Day's High
$41.70
Day's Low
$38.92
Volume
87,931
Avg. Vol
54,630
52-wk High
$55.95
52-wk Low
$15.15

Latest Key Developments (Source: Significant Developments)

Wave Life Sciences Reports Qtrly Loss Per Share $1.26
Wednesday, 9 May 2018 08:00am EDT 

May 9 (Reuters) - WAVE Life Sciences Ltd ::WAVE LIFE SCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.WAVE LIFE SCIENCES LTD QTRLY LOSS PER SHARE $1.26.WAVE LIFE SCIENCES LTD - ENDED Q1 OF 2018 WITH $110.5 MILLION IN CASH AND CASH EQUIVALENTS.WAVE LIFE SCIENCES - EXPECTS CASH, CASH EQUIVALENTS, $170.0 MILLION CASH FROM TAKEDA IN APRIL, ENABLE FUNDING OPERATING, CAPEX REQUIREMENTS TO 2020 END.  Full Article

Wave Life Ended 2017 With $142.5 Mln In Cash, Equivalents
Monday, 12 Mar 2018 08:00am EDT 

March 12 (Reuters) - Wave Life Sciences Ltd ::WAVE LIFE SCIENCES REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.WAVE LIFE SCIENCES LTD - ENDED 2017 WITH $142.5 MILLION IN CASH AND CASH EQUIVALENTS.WAVE LIFE SCIENCES - EXPECTS CASH AND CASH EQUIVALENTS, COMMITTED CASH FROM COLLABORATION WITH TAKEDA, TO FUND REQUIREMENTS TO END OF 2020.  Full Article

Wave Life Sciences Reports Data From Preclinical Studies Testing WVE-3972-01
Monday, 11 Dec 2017 07:00am EST 

Dec 11 (Reuters) - Wave Life Sciences Ltd ::WAVE LIFE SCIENCES - ANNOUNCED DATA FROM PRECLINICAL STUDIES OF WVE-3972-01 FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA.WAVE LIFE SCIENCES - WVE-3972-01 DEMONSTRATED SUBSTANTIAL REDUCTION IN DISEASE-ASSOCIATED BIOMARKERS & SUPERIOR POTENCY TO STEREORANDOM OLIGONUCLEOTIDES.WAVE LIFE SCIENCES LTD - CO INTENDS TO INITIATE CLINICAL TRIALS OF WVE-3972-01 IN ALS AND FTD IN Q4 2018.  Full Article

Wave Life Sciences Q3 net loss of $26.1 million
Thursday, 9 Nov 2017 08:00am EST 

Nov 9 (Reuters) - Wave Life Sciences Ltd ::Wave Life Sciences reports third quarter 2017 financial results and provides business update.Wave Life Sciences Ltd - ‍ Wave reported a net loss of $26.1 million for Q3 of 2017, as compared to a net loss of $17.5 million for Q3 of 2016​.Wave Life Sciences Ltd - qtrly loss per share $0.94‍​.Wave Life Sciences -‍ expects capital resources available, anticipated milestone payments to be sufficient to fund expenses, capex needs into mid-2019​.  Full Article

Wave Life Sciences initiates clinical trial for lead program in Duchenne muscular dystrophy
Monday, 6 Nov 2017 07:00am EST 

Nov 6 (Reuters) - Wave Life Sciences Ltd :Wave Life Sciences initiates clinical trial for lead program in Duchenne muscular dystrophy (DMD).Wave Life Sciences Ltd - ‍data from phase 1 trial for WVE-210201 are expected in Q3 2018​.  Full Article

Teva pharmaceutical reports 5 pct stake in Wave Life Sciences as of Aug 30, 2017 versus 9 percent stake as of Nov 16, 2015
Tuesday, 5 Sep 2017 06:01pm EDT 

Sept 6 (Reuters) - Teva Pharmaceutical Industries Ltd :Teva Pharmaceutical Industries Limited reports 5 percent stake in Wave Life Sciences Ltd as of Aug 30, 2017 versus 9 percent stake as of Nov 16, 2015 - SEC filing‍​.  Full Article

Wave Life Sciences qtrly loss per share $0.92‍​
Wednesday, 9 Aug 2017 08:00am EDT 

Aug 9 (Reuters) - Wave Life Sciences Ltd ::Wave life sciences reports second quarter 2017 financial results and provides business update.Wave life sciences ltd qtrly loss per share $0.92‍​.Wave life sciences - ‍expects cash, cash equivalents available as of June 30, milestone payments, will be sufficient to fund co's operations into mid-2019​.  Full Article

Wave Life Sciences initiates two Phase 1b/2a clinical trials PRECISION-HD1 and PRECISION-HD2 in patients with Huntington’S Disease
Monday, 17 Jul 2017 07:00am EDT 

July 17 (Reuters) - Wave Life Sciences Ltd :Wave Life Sciences Ltd - ‍trials evaluate first allele-specific investigational drugs for Huntington's Disease, WVE-120101 and WVE-120102​.  Full Article

Readcoor and Wave Life Sciences initiate research collaboration
Thursday, 8 Jun 2017 07:00am EDT 

June 8 (Reuters) - Wave Life Sciences Ltd ::Readcoor and Wave Life Sciences initiate research collaboration.Wave Life Sciences Ltd says collaboration aims to unlock next generation stereopure nucleic acid targets with Novel Fisseq Technologies.  Full Article

Wave Life Sciences posts Q1 net loss per share $0.89
Wednesday, 10 May 2017 08:00am EDT 

May 10 (Reuters) - Wave Life Sciences Ltd :Wave Life Sciences reports first quarter 2017 financial results and provides business update.Wave Life Sciences Ltd - two HD programs and DMD program remain on track to enter clinic in 2017.Wave Life SciencesLtd - will announce our next three pipeline candidates later this year.Wave Life Sciences Ltd - is on track to deliver six development programs by end of 2018.Wave Life Sciences Ltd - research and development expenses were $14.7 million for Q1 of 2017 as compared to $4.7 million for same period in 2016.Wave Life Sciences - expects cash, cash equivalents available as of March 31, 2017 will be sufficient to fund operating expenses and capital expenditure into mid-2019.Wave Life Sciences Ltd - had cash and cash equivalents totaling $129.5 million as compared to $150.3 million as of december 31, 2016.Wave Life Sciences Ltd qtrly revenue $676,000.Wave Life Sciences Ltd qtrly net loss per share $0.89.Q1 earnings per share view $-0.77, revenue view $645000.00 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Wave Life Sciences Reports Qtrly Loss Per Share $1.26

* WAVE LIFE SCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE